Abzena PLC Fundamentals Datasheet and Stock Analysis

Profile

Abzena PLC Company Logo
Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups. It offers immunogenicity assessment, which includes EpiScreen, iTope and T Cell Epitope Database (TCED); antibody drug conjugates, which includes ThioBridge linkers; antibody, which includes Composite Human Antibodies and Composite Proteins; optimization of pharmacokinetics, which includes TheraPEG, HiPEG conjugates PEG to poly-histidine motifs and CyPEG, and PolyPEG; cell line development, which includes Composite Human Antibody; process development, Good manufacturing practices (GMP) manufacturing, and small molecules. The Company's Abzena inside includes Composite Human Antibodies and ThioBridge Antibody Drug Conjugates (ADCs).

  • Current Price:
     7.65p
  • Industry:
     Health Care
  • Sector:
     Health Care
  • ISIN:
     GB00BN65QN46
  • Market Sector:
     AIM
  • Main Indices:
     FTSE AIM
  • Country of register:
     Great Britain
  • Currency:
     N/A
  • Shares in Issue:
     214m
  • Market Cap:
     £0m
  • Date Listed:
     10/07/2014
Operation Breakdown
Geographical - by origin (turnover)
Product (turnover)

Loading...

Activity Data Not Available

Company Information

CEO: John Burt  CFO: Julian Smith  Chairman: Ken Cunningham  Non-Executive Director: Peter Grant, Anthony Brampton, Nigel Pitchford Lotta Ljungqvist  Chief Business Officer: Sven Lee  

  • Registrars:
     
  • Address:
     Babraham Research Campus, Babraham, Cambridge, United Kingdom
  • Phone:
     
  • Website:
     
Analysis
Composite Ranking: 32
Historic EPS Ranking: 52
Forecast EPS Ranking: 46
Price Relative Strength: 
Industry Strength: E
SMR Ranking: E
ROCE Ranking: F
Accumulation/Dist: C
Mkt Accumulation/Dist: C
Unbroken Annual EPS: E
Unbroken Interim EPS: E
PEG Current Ranking: A
PEG Forecast Ranking: A
PE Current Ranking: A
PE Forecast Ranking: A
Margin Current Ranking: H
Margin Forecast Ranking: G
Chart
Add Indicator




loading




Takes the average of data over a period of time, and migrates the period across the data series one data point at a time. This formula smooths a data series and makes analysing volatile data easier.
Fundamentals
201420152016201720182019E2020E
Day/Month31/331/331/331/331/331/331/3
Revenue£m5.265.679.8518.6521.95£m27.3135.68
Operating Profit/(loss)£m(4.12)(5.30)10.90(9.74)(14.94)£m0.000.00
Profit Before Tax£m(4.10)(5.22)(10.66)(9.46)(14.75)£m(10.82)(6.96)
Profit After Tax£m(3.55)(4.72)(9.70)(9.12)(14.16)£m0.000.00
Profit After Tax (from discontinued operations)£m0.000.000.000.000.00£m0.000.00
Overall Profit for the Period£m(3.55)(4.72)(9.70)(9.12)(14.16)£m0.000.00
EPS Growth%0.000.000.000.000.00%0.000.00
Earnings Per Sharep(253.00)(7.00)(9.00)(7.00)(7.00)p(4.81)(3.07)
Op. Cash Flow P/Sp0.00(6.97)(9.80)(4.49)(7.11)£0.000.00
Cash Flow P/S Grth%0.000.000.000.000.00%0.000.00
Net Cash Flow P/Sp0.000.000.000.000.00£0.000.00
Capital Exp P/S£0.000.000.000.000.00£0.000.00
Tax Rate%0.000.000.000.000.00%0.000.00
P/E Ratiox0.000.000.000.000.00x0.000.00
P/E Growth£0.000.000.000.000.00£0.000.00
Turnover Per Share£0.000.000.000.000.00£0.000.00
Pre-Tax Profit / Share£0.000.000.000.000.00£0.000.00
Operating Margin%(78.39)(93.47)110.66(52.23)(68.06)%0.000.00
ROCE%0.00(17.97)(24.40)(24.48)(31.00)%0.000.00
ROE%0.00(22.82)(28.15)(23.69)(35.57)%0.000.00
Mkt Cap£m0.00179.95107.1180.3351.41£m0.000.00
Dividend Per Sharep0.000.000.000.000.00p0.000.00
DPS Growth%0.000.000.000.000.00%0.000.00
Dividend Yield%0.000.000.000.000.00%0.000.00
Dividend Coverx0.000.000.000.000.00x0.000.00
Shareholder Funds£m13.5327.8541.0635.9343.69£m0.000.00
Net Borrowings£m(2.76)(15.80)(13.72)(4.13)(6.79)£m0.000.00
Net Assets£m13.5327.8541.0635.9343.69£m0.000.00
Net Assets P/S£0.000.000.000.000.00£0.000.00
Financials
Latest Forecast
Div Yield0.0%0.0%
Div Cover0.0%0.0%
Op Margin-68.1%-39.6%
ROCE0.0%
Director Deals
Traded Action Notifier Price Amount Value
10-Apr-17Transfer ToPeter Grant33.00p 25,000£8,250
16-Aug-16Exercise of optionAnker Lundemose0.02p 75,000£15
27-Jun-16Transfer ToJohn Burt41.00p 98,000£40,180
  Rows per page
Shareholders
214m    Major: 76%    Director: 1%
Notifier Holding Value
John Burt2,120,262¢,200.05
Julian Smith262,084,049.43
Peter Grant58,303,460.18
  Rows per page
Gearing & Cover
News
News Title Date Time Source
Blocklisting update06-Jul-1815:55RNS
Abzena and Telix sign manufacturing agreement02-Jul-1807:00RNS
Annual Report and Accounts19-Jun-1812:28RNS
Funding update14-Jun-1807:00RNS
Final Results04-Jun-1807:00RNS
Notice of full year results29-May-1809:00RNS
Pre-Close Period Trading Update FY201816-Apr-1807:25RNS
Termination of licence agreement09-Apr-1808:25RNS
Issue of Ordinary Shares29-Mar-1817:34RNS
PacificGMP Stanford Settlement05-Mar-1807:00RNS
First PagePrev PageNext Page  Rows per page
Broker Opinion
Date Broker Name Rec Price Old Price Target New Price Target Broker Change
02-Jul-18Peel Hunt LimitedBuy9.10p40.00p40.00pReiteration
08-Jun-15N 1 SingerBuy86.00p0.00p0.00pReiteration
  Rows per page
Notes

This functionality requires you to login

Click here to login
Or register for a new account